__PRESENT__PRESENT
__PRESENT__PRESENT__PRESENT
__PRESENT
__PRESENT
__PRESENT
__PRESENT
__PRESENT__PRESENT__PRESENT__PRESENT__PRESENT
Enter your details to join our mobile app waitlist and receive early access to the Bell Direct App.
Latest stock market news videos & Morning Bell
From the helm: Alterity Therapeutics (ASX:ATH), CEO, David Stamler.
In this episode of From the Helm, Grady chats with Alterity Therapeutics (ASX:ATH) CEO David Stamler, to discuss their neurodegenerative disorder treatment specifically targeting Multiple System Atrophy (MSA), a rare and aggressive disease affecting involuntary functions and motor control.
WeMoney 2026
Best for Market Research Insights
Best for Market Research Insights
WeMoney 2025
Best for Market Research Insights
Best for Market Research Insights
WeMoney 2026
Finalist for IPO Access
Finalist for IPO Access
Highest Overall
Client Satisfaction
2013-2023
Client Satisfaction
2013-2023